Overview of Melanoma in Veterans
Considerations Regarding Epidemiology, Risk Factors, Diagnosis, Prognosis, Survival, and Treatment Introduction Distinct health challenges affect veterans both during and after…
Melanoma Research
11/02/2025
Overview of Melanoma in Veterans
Considerations Regarding Epidemiology, Risk Factors, Diagnosis, Prognosis, Survival, and Treatment Introduction Distinct health challenges affect veterans both during and after…
|
10/22/2025
SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma
Rotterdam, The Netherlands – San Diego, CA – [October 22nd] – SkylineDx today announced that results from its landmark MERLIN_001…
|
|
10/07/2025
You’re Not Out of Options—What To Do After First Line Therapy Fails
Hearing that your treatment for melanoma has stopped working—or that you’ve had to stop because of side effects—can be overwhelming.…
|
08/26/2025
Newly Published Trial Data for Melanoma
Focus on TIGIT Immunotherapy What Is Immunotherapy? Many people with healthy immune systems still develop cancer. Sometimes the immune system…
|
08/26/2025
RP1 + Nivolumab Rejection: Advocating for Patients and Trust in Clinical Trials
FDA Rejects Promising Melanoma Treatment On July 22, 2025, the Food and Drug Administration (FDA) rejected the approval of a…
|
08/11/2025
IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase…
|
|
07/18/2025
Understanding Tumor Genetics and Melanoma: A Recap of Our Latest Webinar
In the age of precision medicine, understanding the genetics of a tumor—not just a person’s inherited DNA—is playing a critical…
|
06/18/2025
Melanoma News and Highlights You Don’t Want to Miss
We know staying informed about melanoma research and treatments is important to you. That’s why we’ve put together some of…
|
06/05/2025
Nivolumab at Micro Doses Works Better than Chemotherapy Against Relapsed Cancer
In Mumbai, India, and other parts of the world, immunotherapy is not always available for every patient who needs it.…
|
06/05/2025
The Time of Day Pembrolizumab is Administered May Link to Patient Survival
Timing matters. A study presented at the annual meeting of the American Society of Clinical Oncology in Chicago suggests that…
|
Recent Posts
Apr. 10, 2026
FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients
Apr. 07, 2026
2026 National Sunscreen Partner
Apr. 07, 2026
Young Adult Cancer & Mental Health
Apr. 02, 2026
Uveal Melanoma Webinar: Part II — Navigating Treatment in the Metastatic Setting
Mar. 26, 2026